

Peter J M Openshaw

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5851088/peter-j-m-openshaw-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

247
papers

16,322
citations

67
h-index

122
g-index

340
ext. papers

20,954
ext. citations

11.7
avg, IF

6.64
L-index

#	Paper	IF	Citations
247	Using correlates to accelerate vaccinology.. <i>Science</i> , 2022 , 375, 22-23	33.3	3
246	Respiratory Syncytial Virus-Associated Hospital Admissions and Bed Days in Children . <i>Journal of Infectious Diseases</i> , 2022 ,	7	2
245	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.. <i>Nature Medicine</i> , 2022 ,	50.5	23
244	Whole genome sequencing reveals host factors underlying critical Covid-19.. <i>Nature</i> , 2022 ,	50.4	8
243	SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.. <i>Lancet, The</i> , 2022 ,	40	20
242	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.. <i>Scientific Reports</i> , 2022 , 12, 6843	4.9	0
241	H NMR Signals from Urine Excreted Protein Are a Source of Bias in Probabilistic Quotient Normalization.. <i>Analytical Chemistry</i> , 2022 , 94, 6919-6923	7.8	
240	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac179	1	2
239	Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus.. <i>Frontiers in Immunology</i> , 2022 , 13, 807104	8.4	0
238	Controlled Human Infection Challenge Studies with RSV. <i>Current Topics in Microbiology and Immunology</i> , 2022 ,	3.3	
237	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2021 , 141, 147	6.3	3
236	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. 2021 ,		25
235	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. <i>BMJ Open</i> , 2021 , 11, e055435	3	1
234	Resilience of the respiratory microbiome in controlled adult RSV challenge study. <i>European Respiratory Journal</i> , 2021 ,	13.6	0
233	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021 , 591, 92-98	50.4	451
232	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021 , 12, 1951	17.4	25
231	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021 , 6,	28	82

230	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. <i>Obesity</i> , 2021 , 29, 1223-1230 ⁸	13
229	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021 , 184, 1171-1187.e20	56.2 331
228	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 699-711	35.1 54
227	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021 , 12, 2055	17.4 37
226	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 349-359	35.1 70
225	Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. <i>Emerging Infectious Diseases</i> , 2021 , 27, 1-9	10.2 4
224	COVID-19 pneumothorax in the UK: a prospective observational study using the ISARIC WHO clinical characterisation protocol. <i>European Respiratory Journal</i> , 2021 , 58,	13.6 8
223	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 773-785	35.1 35
222	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , 2021 , 398, 223-237	40 39
221	Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe-results from the PED-MERMAIDS multicentre case-control study. <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6 3
220	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. <i>BMC Infectious Diseases</i> , 2021 , 21, 717	4 2
219	Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 694-703.e12	11.5 5
218	Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. <i>Trends in Microbiology</i> , 2021 , 29, 648-662	12.4 13
217	Innate-like Gene Expression of Lung-Resident Memory CD8 T Cells during Experimental Human Influenza: A Clinical Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 826-841 ^{10.2}	2
216	Offspring born to influenza A virus infected pregnant mice have increased susceptibility to viral and bacterial infections in early life. <i>Nature Communications</i> , 2021 , 12, 4957	17.4 3
215	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021 , 12, 5125	17.4 3
214	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , 2021 , 2, e354-e365	22.2 61
213	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. <i>Lancet Regional Health - Europe</i> , 2021 , 8, 100186	43

212	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. <i>Lancet, The</i> , 2021 , 398, 1037-1038	40	25
211	A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease. <i>Journal of Infectious Diseases</i> , 2021 ,	7	1
210	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021 , 374, eabj3624	33.3	26
209	Corticosteroid Use in Otolaryngology: Current Considerations During the COVID-19 Era. <i>Otolaryngology - Head and Neck Surgery</i> , 2021 , 1945998211064275	5.5	3
208	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <i>Thorax</i> , 2021 ,	7.3	4
207	Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 717-725	35.1	212
206	Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration. <i>ESMO Open</i> , 2020 , 5, e000825	6	5
205	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 851-858	2.4	133
204	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , 2020 , 20, 770-772	25.5	22
203	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 822-830	35.1	72
202	Using imaging to combat a pandemic: rationale for developing the UK National COVID-19 Chest Imaging Database. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	9
201	Toward unified molecular surveillance of RSV: A proposal for genotype definition. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 274-285	5.6	15
200	A High-Fat Diet Increases Influenza A Virus-Associated Cardiovascular Damage. <i>Journal of Infectious Diseases</i> , 2020 , 222, 820-831	7	15
199	Seasonal and pandemic influenza: 100 years of progress, still much to learn. <i>Mucosal Immunology</i> , 2020 , 13, 566-573	9.2	25
198	Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. <i>BMJ, The</i> , 2020 , 369, m1985	5.9	1552
197	Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. <i>Journal of Clinical Investigation</i> , 2020 , 130, 523-538	15.9	20
196	Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. <i>Lancet, The</i> , 2020 , 395, 42-52	40	35
195	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1656-1665	10.2	72

194	Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. <i>Science</i> , 2020 , 370,	33.3	46
193	Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. <i>Journal of Infectious Diseases</i> , 2020 , 222, S666-S671	7	4
192	Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). <i>Journal of Infectious Diseases</i> , 2020 , 222, S658-S665	7	3
191	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. <i>Viruses</i> , 2020 , 12,	6.2	23
190	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020 , 21, 1336-1345	19.1	615
189	Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. <i>BMJ, The</i> , 2020 , 370, m3249	5.9	259
188	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. <i>BMJ, The</i> , 2020 , 370, m3339	5.9	378
187	Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020 , 222, S577-S583	7	101
186	The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2020 , 222, S563-S569	7	37
185	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020 , 222, S570-S576	7	24
184	Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. <i>Journal of Infectious Diseases</i> , 2020 , 222, S584-S591	7	3
183	A41 Deep sequencing of respiratory syncytial virus links viral diversity to disease severity. <i>Virus Evolution</i> , 2019 , 5,	3.7	78
182	Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 342-345.e7	11.5	4
181	Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 481-492	10.2	12
180	Transcriptional profiling unveils type I and II interferon networks in blood and tissues across diseases. <i>Nature Communications</i> , 2019 , 10, 2887	17.4	32
179	Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	16
178	OMIP-062: A 14-Color, 16-Antibody Panel for Immunophenotyping Human Innate Lymphoid, Myeloid and T Cells in Small Volumes of Whole Blood and Pediatric Airway Samples. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019 , 95, 1231-1235	4.6	6
177	Respiratory syncytial virus (RSV): a scourge from infancy to old age. <i>Thorax</i> , 2019 , 74, 986-993	7.3	28

176	Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	11
175	Biphasic activation of complement and fibrinolysis during the human nasal allergic response. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 1892-1895.e6	11.5	3
174	Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1074-1084	10.2	45
173	The 1918 Influenza Pandemic: one hundred years of progress, but where now?. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 588-589	35.1	5
172	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. <i>Lancet Infectious Diseases</i> , 2018 , 18, e295-e311	25.5	218
171	Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018 , 73, 1151-1181	9.3	27
170	Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. <i>Journal of Virology</i> , 2018 , 92,	6.6	39
169	Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. <i>Nature Immunology</i> , 2018 , 19, 625-635	19.1	82
168	RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel. <i>Immunity</i> , 2017 , 46, 171-173	32.3	1
167	Protective and Harmful Immunity to RSV Infection. <i>Annual Review of Immunology</i> , 2017 , 35, 501-532	34.7	116
166	Maternal immunisation: collaborating with mother nature. <i>Lancet Infectious Diseases</i> , 2017 , 17, e197-e208	25.5	92
165	Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. <i>Lancet Infectious Diseases</i> , 2017 , 17, e223-e234	25.5	60
164	Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis. <i>Journal of Infectious Diseases</i> , 2017 , 215, 1240-1244	7	15
163	Vaccines in the Prevention of Viral Pneumonia. <i>Clinics in Chest Medicine</i> , 2017 , 38, 155-169	5.3	7
162	Issues in vaccinology: Present challenges and future directions. <i>European Journal of Immunology</i> , 2017 , 47, 2017-2025	6.1	15
161	Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing. <i>Progress in Preventive Medicine (New York, N Y)</i> , 2017 , 2, e006	0.7	5
160	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. <i>JCI Insight</i> , 2017 , 2, e91868	9.9	39
159	The Helminth-Derived Immunomodulator AvCystatin Reduces Virus Enhanced Inflammation by Induction of Regulatory IL-10+ T Cells. <i>PLoS ONE</i> , 2016 , 11, e0161885	3.7	14

158	Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1040-9	10.2	163
157	Effect of ethnicity on care pathway and outcomes in patients hospitalized with influenza A(H1N1)pdm09 in the UK. <i>Epidemiology and Infection</i> , 2015 , 143, 1129-38	4.3	8
156	Antiviral B cell and T cell immunity in the lungs. <i>Nature Immunology</i> , 2015 , 16, 18-26	19.1	90
155	RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. <i>Nature Communications</i> , 2015 , 6, 10224	17.4	155
154	How should influenza be treated? Focus on antivirals. <i>Vaccine</i> , 2015 , 33, 7033-6	4.1	
153	Nasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness. <i>PLoS ONE</i> , 2015 , 10, e0135363	3.7	12
152	Current concepts and progress in RSV vaccine development. <i>Expert Review of Vaccines</i> , 2014 , 13, 333-44	5.2	40
151	Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. <i>Journal of Virology</i> , 2014 , 88, 6128-36	6.6	97
150	Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. <i>Journal of Virology</i> , 2014 , 88, 13269-83	6.6	58
149	Neuraminidase inhibitors for influenza complications--Authors' reply. <i>Lancet, The</i> , 2014 , 384, 1261-2	4.0	1
148	Antivirals for influenza: where now for clinical practice and pandemic preparedness?. <i>Lancet, The</i> , 2014 , 384, 386-7	4.0	10
147	Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 827-35.e3	11.5	33
146	Live attenuated B. pertussis BPZE1 rescues the immune functions of Respiratory Syncytial virus infected human dendritic cells by promoting Th1/Th17 responses. <i>PLoS ONE</i> , 2014 , 9, e100166	3.7	9
145	Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. <i>Journal of Virology</i> , 2014 , 88, 604-11	6.6	34
144	Immunity to RSV in Early-Life. <i>Frontiers in Immunology</i> , 2014 , 5, 466	8.4	113
143	Open source clinical science for emerging infections. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 8-9	25.5	58
142	Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 194-202	10.2	33
141	Protective and dysregulated T cell immunity in RSV infection. <i>Current Opinion in Virology</i> , 2013 , 3, 468-74	7.5	78

140	Microbes and mucosal immune responses in asthma. <i>Lancet, The</i> , 2013 , 381, 861-73	4.0	118
139	Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. <i>European Respiratory Journal</i> , 2013 , 41, 824-31	13.6	34
138	Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. <i>Journal of Virology</i> , 2013 , 87, 10946-54	6.6	73
137	Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice. <i>Mucosal Immunology</i> , 2013 , 6, 704-17	9.2	9
136	A gene expression signature for RSV: clinical implications and limitations. <i>PLoS Medicine</i> , 2013 , 10, e1001550	15.0	5
135	Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 2987-92	11.5	76
134	Neonatal antibody responses are attenuated by interferon- γ produced by NK and T cells during RSV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 5576-81	11.5	29
133	An evaluation of community assessment tools (CATs) in predicting use of clinical interventions and severe outcomes during the A(H1N1)pdm09 pandemic. <i>PLoS ONE</i> , 2013 , 8, e75384	3.7	4
132	The mouse model of respiratory syncytial virus disease. <i>Current Topics in Microbiology and Immunology</i> , 2013 , 372, 359-69	3.3	18
131	IFITM3 restricts the morbidity and mortality associated with influenza. <i>International Journal of Infectious Diseases</i> , 2012 , 16, e79	10.5	5
130	Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection. <i>Journal of Virology</i> , 2012 , 86, 10456-61	6.6	26
129	Predominance of heterosubtypic IFN- γ -only-secreting effector memory T cells in pandemic H1N1 naive adults. <i>European Journal of Immunology</i> , 2012 , 42, 2913-24	6.1	29
128	Human microbial challenge: the ultimate animal model. <i>Lancet Infectious Diseases, The</i> , 2012 , 12, 903-5	25.5	33
127	Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. <i>PLoS ONE</i> , 2012 , 7, e34428	3.7	12
126	The microbiology of asthma. <i>Nature Reviews Microbiology</i> , 2012 , 10, 459-71	22.2	130
125	Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. <i>Current Opinion in Infectious Diseases</i> , 2012 , 25, 687-94	5.4	18
124	Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. <i>Mucosal Immunology</i> , 2012 , 5, 161-72	9.2	133
123	OX40 ligand and programmed cell death 1 ligand 2 expression on inflammatory dendritic cells regulates CD4 T cell cytokine production in the lung during viral disease. <i>Journal of Immunology</i> , 2012 , 188, 1647-55	5.3	12

122	IFITM3 restricts the morbidity and mortality associated with influenza. <i>Nature</i> , 2012 , 484, 519-23	50.4	537
121	Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. <i>Thorax</i> , 2012 , 67, 709-17	7.3	66
120	IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. <i>PLoS ONE</i> , 2012 , 7, e32371	3.7	93
119	The comparative clinical course of pregnant and non-pregnant women hospitalised with influenza A(H1N1)pdm09 infection. <i>PLoS ONE</i> , 2012 , 7, e41638	3.7	13
118	Severe Influenza: Clinical Features and Treatment Options. <i>Current Respiratory Medicine Reviews</i> , 2012 , 8, 208-227	0.3	3
117	Contribution of cytokines to pathology and protection in virus infection. <i>Current Opinion in Virology</i> , 2011 , 1, 184-95	7.5	21
116	Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. <i>European Respiratory Journal</i> , 2011 , 38, 401-8	13.6	44
115	Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009-2010. <i>Emerging Infectious Diseases</i> , 2011 , 17, 592-8	10.2	43
114	RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. <i>Journal of Infectious Diseases</i> , 2011 , 203, 85-94	7	55
113	Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from inter-pandemic community-acquired pneumonia in adults. <i>Thorax</i> , 2011 , 66, 247-52	7.3	24
112	Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. <i>PLoS ONE</i> , 2011 , 6, e18120	3.7	44
111	Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. <i>Journal of Virology</i> , 2010 , 84, 5294-302	6.6	26
110	CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. <i>Journal of Virology</i> , 2010 , 84, 8790-8	6.6	120
109	Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. <i>Journal of Immunology</i> , 2010 , 185, 5384-91	5.3	34
108	Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). <i>Thorax</i> , 2010 , 65, 645-51	7.3	179
107	Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. <i>Journal of Virology</i> , 2010 , 84, 4073-82	6.6	46
106	Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. <i>Mucosal Immunology</i> , 2010 , 3, 422-4	9.2	6
105	Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable alodepletion strategy. <i>Blood</i> , 2010 , 115, 396-407	2.2	43

104	The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. <i>PLoS ONE</i> , 2010 , 5, e9381	3.7	42
103	Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. <i>Journal of Immunology</i> , 2009 , 182, 1174-81	5.3	56
102	Emerging drugs for respiratory syncytial virus infection. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 2073-17	4.2	42
101	Crossing barriers: infections of the lung and the gut. <i>Mucosal Immunology</i> , 2009 , 2, 100-2	9.2	35
100	IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. <i>Journal of Immunology</i> , 2009 , 183, 7006-13	5.3	33
99	Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. <i>Clinical and Experimental Allergy</i> , 2008 , 38, 1016-24	4.1	42
98	Poly(lactide-co-glycolide) (PLG) microparticles modify the immune response to DNA vaccination. <i>Vaccine</i> , 2008 , 26, 753-61	4.1	17
97	Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. <i>Journal of Virology</i> , 2008 , 82, 4441-8	6.6	155
96	The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. <i>Journal of Virology</i> , 2008 , 82, 4115-24	6.6	89
95	Susan Elizabeth Openshaw (née Scott Stokes) 2008 , 336, 621.6-621		78
94	Virally delivered cytokines alter the immune response to future lung infections. <i>Journal of Virology</i> , 2007 , 81, 13105-11	6.6	27
93	Functional Characterisation of Alloreactive T-Cells Identifies CD25 and CD71 as the Optimal Targets for Allogeneic Depletion Strategies. <i>Blood</i> , 2007 , 110, 2183-2183	2.2	
92	Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 871-6	10.2	139
91	Role of CCL5 (RANTES) in viral lung disease. <i>Journal of Virology</i> , 2006 , 80, 8151-7	6.6	84
90	Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. <i>Journal of Virology</i> , 2006 , 80, 4521-7	6.6	90
89	Bronchiolitis. <i>Lancet, The</i> , 2006 , 368, 312-22	4.0	327
88	A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. <i>Nature Medicine</i> , 2006 , 12, 905-7	50.5	161
87	The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. <i>Respiratory Research</i> , 2005 , 6, 70	7.3	38

86	Immune responses and disease enhancement during respiratory syncytial virus infection. <i>Clinical Microbiology Reviews</i> , 2005 , 18, 541-55	34	237
85	Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 604-8	3.4	2
84	Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. <i>Journal of Virology</i> , 2005 , 79, 2050-7	6.6	48
83	Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. <i>Proceedings of the American Thoracic Society</i> , 2005 , 2, 121-5		36
82	Vaccines for the prevention of respiratory viral infections: problems and current status. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 681-9	5.9	2
81	Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. <i>Journal of General Virology</i> , 2004 , 85, 3017-3026	4.9	16
80	What does the peripheral blood tell you in SARS?. <i>Clinical and Experimental Immunology</i> , 2004 , 136, 11-2	6.2	17
79	Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. <i>Microbes and Infection</i> , 2004 , 6, 666-75	9.3	12
78	Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. <i>Microbes and Infection</i> , 2004 , 6, 1049-55	9.3	27
77	Childhood infections, the developing immune system, and the origins of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2004 , 114, 1275-7	11.5	38
76	Latency and persistence of respiratory syncytial virus despite T cell immunity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 801-5	10.2	126
75	Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. <i>Virus Research</i> , 2004 , 106, 1-13	6.4	18
74	Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. <i>Vaccine</i> , 2004 , 23, 215-21	4.1	33
73	Mucosal Vaccination 2004 , 343-363		1
72	. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, S58-S65	3.4	16
71	Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, S58-64; discussion S64-5	3.4	85
70	Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner. <i>Infection and Immunity</i> , 2003 , 71, 3384-91	3.7	23
69	RSV bronchiolitis, gammadelta T cells and asthma: are they linked?. <i>Clinical and Experimental Immunology</i> , 2003 , 131, 197-8	6.2	4

68	Where is SARS now?. <i>Thorax</i> , 2003 , 58, 650-1	7.3	
67	Current research on respiratory viral infections: Fourth International Symposium. <i>Antiviral Research</i> , 2002 , 55, 227-78	10.8	26
66	Increased aeroallergen-specific interleukin-4-producing T cells in asthmatic adults. <i>Clinical and Experimental Allergy</i> , 2002 , 32, 1739-44	4.1	12
65	Development of vaccines against common colds. <i>British Medical Bulletin</i> , 2002 , 62, 99-111	5.4	15
64	Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. <i>Journal of Immunology</i> , 2002 , 169, 2210-4	5.3	95
63	Pulmonary defences to acute respiratory infection. <i>British Medical Bulletin</i> , 2002 , 61, 1-12	5.4	70
62	Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. <i>Journal of Experimental Medicine</i> , 2002 , 196, 1381-6	16.6	211
61	Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. <i>European Respiratory Journal</i> , 2002 , 20, 376-82	13.6	61
60	Potential therapeutic implications of new insights into respiratory syncytial virus disease. <i>Respiratory Research</i> , 2002 , 3 Suppl 1, S15-20	7.3	25
59	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. <i>European Journal of Immunology</i> , 2001 , 31, 1438-46	6.1	59
58	Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. <i>European Journal of Immunology</i> , 2001 , 31, 2566-73	6.1	240
57	Long-term persistence and reactivation of T cell memory in the lung of mice infected with respiratory syncytial virus. <i>European Journal of Immunology</i> , 2001 , 31, 2574-82	6.1	78
56	An improved protocol for measuring cytotoxic T cell activity in anatomic compartments with low cell numbers. <i>Journal of Immunological Methods</i> , 2001 , 257, 155-61	2.5	15
55	Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. <i>Journal of Experimental Medicine</i> , 2001 , 193, 785-92	16.6	96
54	Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. <i>Journal of Immunology</i> , 2001 , 166, 1106-13	5.3	89
53	Potential mechanisms causing delayed effects of respiratory syncytial virus infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 163, S10-3	10.2	18
52	Immunopathogenesis of vaccine-enhanced RSV disease. <i>Vaccine</i> , 2001 , 20 Suppl 1, S27-31	4.1	119
51	The protective effect of childhood infections. <i>BMJ: British Medical Journal</i> , 2001 , 322, 376-7		20

50	Partners in crime: co-infections in the developing world. <i>Clinical and Experimental Immunology</i> , 2000 , 122, 296-9	6.2	8
49	Reply to rook. <i>Trends in Immunology</i> , 2000 , 21, 249-50		16
48	Flow cytometric measurement of intracellular cytokines. <i>Journal of Immunological Methods</i> , 2000 , 243, 107-24	2.5	181
47	IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of respiratory syncytial virus but do not enhance the severity of illness in CD8 T cell-immunodeficient conditions. <i>Journal of Immunology</i> , 2000 , 165, 7109-15	5.3	57
46	Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1317-26	16.6	106
45	Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner?. <i>Current Opinion in Microbiology</i> , 1999 , 2, 410-4	7.9	14
44	Respiratory syncytial virus and wheeze. <i>Lancet, The</i> , 1999 , 354, 1997-8	4.0	20
43	Anaphylactic sensitization to aeroantigen during respiratory virus infection. <i>Clinical and Experimental Allergy</i> , 1998 , 28, 1501-8	4.1	52
42	Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. <i>Journal of Pediatrics</i> , 1998 , 133, 272-4	3.6	46
41	Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. <i>Journal of Experimental Medicine</i> , 1998 , 187, 1921-8	16.6	117
40	CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. <i>European Journal of Immunology</i> , 1997 , 27, 3341-9	6.1	202
39	Mouse gamma delta TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to alpha beta TCR+NK1.1+ thymocytes. <i>European Journal of Immunology</i> , 1996 , 26, 1424-9	6.1	59
38	Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. <i>Journal of Experimental Medicine</i> , 1996 , 183, 901-13	16.6	360
37	Beneficial and Harmful Immune Responses in the Respiratory Tract 1996 , 449-457		2
36	Immunopathological mechanisms in respiratory syncytial virus disease. <i>Seminars in Immunopathology</i> , 1995 , 17, 187-201		66
35	Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. <i>Journal of Experimental Medicine</i> , 1995 , 182, 1357-67	16.6	495
34	Immunity and immunopathology to respiratory syncytial virus. The mouse model. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995 , 152, S59-62	10.2	108
33	Distinct types of lung disease caused by functional subsets of antiviral T cells. <i>Journal of Experimental Medicine</i> , 1994 , 179, 81-9	16.6	269

32	Response from Openshaw. <i>Trends in Microbiology</i> , 1994 , 2, 149-150	12.4	1
31	Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. <i>Vaccine</i> , 1993 , 11, 431-7	4.1	53
30	CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. <i>Clinical and Experimental Immunology</i> , 1992 , 88, 527-36	6.2	123
29	Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. <i>International Immunology</i> , 1992 , 4, 493-500	4.9	192
28	Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. <i>Journal of Virology</i> , 1992 , 66, 2102-10	6.6	106
27	The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. <i>Journal of Virology</i> , 1990 , 64, 1683-9	6.6	87
26	MHC and antigen presentation. <i>Trends in Immunology</i> , 1989 , 10, 396-7		3
25	Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. <i>Journal of Experimental Medicine</i> , 1988 , 168, 1163-8	16.6	399
24	Changes in rib cage geometry during childhood. <i>Thorax</i> , 1984 , 39, 624-7	7.3	93
23	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge		9
22	Respiratory syncytial virus84-109		5
21	COVID-19 and beyond: 'a call for action and 'audacious solidarity to all the citizens and nations, 'it is humanity's fight. <i>F1000Research</i> , 9 , 1130	3.6	2
20	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. <i>SSRN Electronic Journal</i> ,	1	40
19	Amplicon based MinION sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from patients with COVID-19		24
18	Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study		1
17	Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.		3
16	Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study		7
15	Robust, reproducible clinical patterns in hospitalised patients with COVID-19		7

14	Genetic mechanisms of critical illness in Covid-19	51
13	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses	7
12	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2	6
11	Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19	4
10	Development and validation of the 4C Deterioration model for adults hospitalised with COVID-19	6
9	Changes in UK hospital mortality in the first wave of COVID-19: the ISARIC WHO Clinical Characterisation Protocol prospective multicentre observational cohort study	4
8	Identification and quantification of SARS-CoV-2 leader subgenomic mRNA gene junctions in nasopharyngeal samples shows phasic transcription in animal models of COVID-19 and dysregulation at later time points that can also be identified in humans	1
7	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol	7
6	Physical, cognitive and mental health impacts of COVID-19 following hospitalisation: a multi-centre prospective cohort study	17
5	Sequence analysis of SARS-CoV-2 in nasopharyngeal samples from patients with COVID-19 illustrates population variation and diverse phenotypes, placing the in vitro growth properties of B.1.1.7 and B.1.351 lineage viruses in context	2
4	Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study	3
3	Whole genome sequencing identifies multiple loci for critical illness caused by COVID-19	2
2	Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study	3
1	Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype	2